Patients Act

Patient advocacy organization for patient rights and access to all approved treatments.

Based in IL

Share:𝕏LinkedInFacebook
🤖

AI Overview

With $140K in lobbying spend across 3 quarterly filings, Patients Act is an active lobbying client. Their lobbying covers 2 issue areas.

$140K
Total Spend
1
Years Active
1
Firms Hired
1
Lobbyists Deployed
2
Issues Lobbied

Spending Trend

View as table
YearLobbying Spend
2025$140K

Issues Lobbied

Medicare/MedicaidMED

Lobbying Firms

Saluber Strategies

Lobbyists

Denise Morrisey

Government Agencies Targeted

These are the government entities that Patients Act disclosed contacting in their lobbying filings.

Centers For Medicare and Medicaid Services (CMS)White House OfficeHealth & Human Services, Dept of (HHS)
View all agency pressure data →

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Medicare/Medicaid, MED

Issues related to skin cancer coverage in Physician Fee Schedule.

Related Analysis

📈 Client Trajectories
See how this client compares to others over time
🎯 Market Concentration
How concentrated is the lobbying market?
🚀 Spending Momentum
Which issues are surging right now?

Related Investigations

Federal Lobbying Statistics 2025
The definitive stats — $37.7B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.

Similar Clients

American Association of Orthopaedic Surgeons
$14.7M total spend
American Academy of Pediatrics
$8.4M total spend
Muscular Dystrophy Association, INC.
$3.5M total spend
American Academy of Orthopaedic Surgeons
$1.2M total spend
Horizon Therapeutics USA INC
$1.2M total spend

Explore More

← All Clients⚖️ Compare Clients💵 ROI Calculator🔍 Investigations📖 How Lobbying Works🕸️ Network Analysis🏛️ Agency Pressure

Data Sources: Senate LDA Filings

Last updated: February 2026

This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.